Details of the Drug

General Information of Drug (ID: DM70IK5)

Drug Name

Marinol

Synonyms

Dronabinol; TETRAHYDROCANNABINOL; delta9-Tetrahydrocannabinol; delta9-THC; Deltanyne; Dronabinolum; delta-9-tetrahydrocannabinol; Abbott 40566; delta-9-THC; delta(9)-THC; 1972/8/3; delta1-THC; delta(sup 1)-Thc; delta(sup 9)-Thc; 1-trans-delta-9-Tetrahydrocannabinol; THC; Namisol; Dronabinolum [Latin]; 9-tetrahydrocannabinol; delta(9)-Tetrahydrocannabinol; delta(1)-Tetrahydrocannabinol; (-)-delta9-trans-Tetrahydrocannabinol; delta1-Tetrahydrocannabinol; 1-trans-delta9-Tetrahydrocannabinol; delta(9)-Tetrahydrocannibinol; SP; Compassia; Ganja; Hashish; Marincap; MaxEPA; Omegaven; Promega; Relivar; Sonergx; Tetranabinex; Cannabis resin; Drona binol; QCD 84924; SP 104; Tetrahydrocannabinol delta9; CAT-310; DELTA1-THC; DELTA1-Tetrahydrocannabinol;DELTA9-THC; DRG-0138; Delta-THC; Delta1-THC; Delta1-Tetrahydrocannabinol; Delta9-THC; Delta9-Tetrahydrocannabinol; Delta9-Tetrahydrocannabinol solution; Dronabinol [USAN:INN]; Marinol (TN); Pro-Mega;QCD-84924; Trans-tetrahydrocannabinol; DELTA9-trans-Tetrahydrocannabinol; Delta(1)-THC; Delta(1)-Tetrahydrocannabinol; Delta(9)-THC; Delta(9)-Tetrahydrocannabinol; Delta(9)-Tetrahydrocannibinol; Delta(sup 1)-Tetrahydrocannabinol; Delta(sup 1)-Thc; Delta(sup 9)-Tetrahydrocannabinol; Delta(sup 9)-Thc; Delta(sup9)-THC; Delta-9-THC; Delta-9-tetrahydrocannabinol; Delta1-Tetrahydrocannabinol (VAN); Delta9-Tetrahydrocannabinol (VAN); Delta9-trans-Tetrahydrocannabinol; Dronabinol (USP/INN); Omega-3-Fatty acid; THC-delta-9; Trans-delta9-Tetrahydrocannabinol; Cannabinol, tetrahydro-(6CI); Fish oils, n-3 fatty acid-high; Fish oils, omega-3 fatty acid-high; L-delta(sup 1)-tetrahydrocannabinol; L-delta1-trans-Tetrahydrocannabinol; L-trans-delta9-Tetrahydrocannabinol; Trans-delta-9-Tetrahydrocannabinol; Cannabinol, Delta1-tetrahydro-(7CI); Fats and Glyceridic oils, fish, n-3 fatty acid-high; L-delta1-Tetrahydrocannabinol; Trans-DELTA9-Tetrahydrocannabinol; L-delta1-trans-Tetrahydrocannabinol;L-trans-delta9-Tetrahydrocannabinol; Tetrahydrocannabinols (-)-delta1-3,4-trans-form; (-)-DELTA1-Tetrahydrocannabinol; (-)-DELTA9-THC; (-)-DELTA9-Tetrahydrocannabinol; (-)-DELTA9-trans-Tetrahydrocannabinol; (-)-delta(sup9)-trans-Tetrahydrocannabinol; (-)-3,4-trans-Delta1-Tetrahydrocannabinol; (-)-delta(sup 1)-3,4-trans-Tetrahydrocannabinol; (-)-delta1-Tetrahydrocannabinol; (-)-delta9-(trans)-Tetrahydrocannabinol; (-)-delta9-Tetrahydrocannabinol; (-)-trans-DELTA9-Tetrahydrocannabinol; (-)-trans-Delta1-Tetrahydrocannabinol; (-)-trans-Delta9-THC; (-)-trans-delta9-Tetrahydrocannabinol; (L)-delta1-Tetrahydrocannabinol; (l)-delta(sup 1)-Tetrahydrocannabinol; (l)-delta1-Tetrahydrocannabinol; 1-trans-delta(sup9)-tetrahydrocannabinol; 1-trans-D9-Tetrahydrocannabinol; 1-trans-delta(sup 9)-Tetrahydrocannabinol; 14C-DELTA1-Tetrahydrocannabinol; 6H-Dibenzo; 9-delta-Tetrahydrocannabinol; 9-ene-Tetrahydrocannabinol; Delta(9)-tetrahydrocannabinol

Indication

Disease Entry	ICD 11	Status	REF
Anorexia nervosa cachexia	6B80	Approved	[1]
Chemotherapy-induced nausea	MD90	Phase 2/3	[2]
------------------------------------------------------------------------------------

Therapeutic Class

Analgesics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

314.5

Logarithm of the Partition Coefficient (xlogp)

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Clearance: The drug present in the plasma can be removed from the body at the rate of 3.2 mL/min/kg [4]
Elimination: 0.5% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 4 hours [4]
Metabolism: The drug is metabolized via the liver [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.9086 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.05% [4]
Vd: The volume of distribution (Vd) of drug is 10 L/kg []

Chemical Identifiers

Formula: C21H30O2
IUPAC Name: (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol
Canonical SMILES: CCCCCC1=CC(=C2[C@@H]3C=C(CC[C@H]3C(OC2=C1)(C)C)C)O
InChI: InChI=1S/C21H30O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15/h11-13,16-17,22H,5-10H2,1-4H3/t16-,17-/m1/s1
InChIKey: CYQFCXCEBYINGO-IAGOWNOFSA-N

Cross-matching ID

PubChem CID: 16078
ChEBI ID: CHEBI:66964
CAS Number: 1972-08-3
DrugBank ID: DB00470
TTD ID: D0P1FO
INTEDE ID: DR0548
ACDINA ID: D00217

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cannabinoid receptor 1 (CB1)	TT6OEDT	CNR1_HUMAN	Agonist	[7]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[8]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[9]
Cytochrome P450 1A1 (CYP1A1)	DE6OQ3W	CP1A1_HUMAN	Substrate	[10]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[11]
Cytochrome P450 2A6 (CYP2A6)	DEJVYAZ	CP2A6_HUMAN	Substrate	[12]
Prostaglandin G/H synthase 1 (COX-1)	DE073H6	PGH1_HUMAN	Substrate	[8]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
(Lyso)-N-acylphosphatidylethanolamine lipase (ABHD4)	OTQK3M9X	ABHD4_HUMAN	Gene/Protein Processing	[13]
1-acyl-sn-glycerol-3-phosphate acyltransferase beta (AGPAT2)	OT5I4Y9K	PLCB_HUMAN	Gene/Protein Processing	[13]
10 kDa heat shock protein, mitochondrial (HSPE1)	OT7JSZLB	CH10_HUMAN	Gene/Protein Processing	[14]
14-3-3 protein epsilon	OT3WQXNA	1433E_HUMAN	Gene/Protein Processing	[15]
2-oxoglutarate and iron-dependent oxygenase JMJD4 (JMJD4)	OTYZGH63	JMJD4_HUMAN	Gene/Protein Processing	[13]
26S proteasome non-ATPase regulatory subunit 1 (PSMD1)	OTW258OV	PSMD1_HUMAN	Gene/Protein Processing	[16]
26S proteasome non-ATPase regulatory subunit 8 (PSMD8)	OTY6X27P	PSMD8_HUMAN	Gene/Protein Processing	[16]
26S proteasome regulatory subunit 10B (PSMC6)	OTG8997V	PRS10_HUMAN	Gene/Protein Processing	[13]
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase (EBP)	OTSMGKXQ	EBP_HUMAN	Gene/Protein Processing	[16]
4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT5 (FUT5)	OTOPGL9M	FUT5_HUMAN	Gene/Protein Processing	[13]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Anorexia nervosa cachexia

ICD Disease Classification

6B80

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Cannabinoid receptor 1 (CB1)	DTT	CNR1	5.59E-02	-0.22	-0.45
Cannabinoid receptor 1 (CB1)	DTT	CNR1	7.68E-01	-0.06	-0.46
Cytochrome P450 2A6 (CYP2A6)	DME	CYP2A6	6.24E-01	6.79E-02	2.28E-01
Cytochrome P450 2A6 (CYP2A6)	DME	CYP2A6	2.82E-01	-4.18E-02	-2.80E-01
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	7.39E-01	1.54E-02	4.74E-02
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	4.64E-02	-8.21E-02	-7.11E-01
Cytochrome P450 1A1 (CYP1A1)	DME	CYP1A1	2.32E-01	-3.66E-02	-1.30E-01
Cytochrome P450 1A1 (CYP1A1)	DME	CYP1A1	6.55E-01	1.27E-02	8.44E-02
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	8.99E-01	-6.93E-03	-1.36E-02
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	9.21E-01	7.31E-03	6.10E-02
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	4.66E-01	4.25E-02	1.20E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	4.75E-01	5.15E-02	3.64E-01
Prostaglandin G/H synthase 1 (COX-1)	DME	PTGS1	3.26E-01	1.33E-01	1.12E-01
Prostaglandin G/H synthase 1 (COX-1)	DME	PTGS1	2.34E-01	4.46E-02	4.03E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Marinol (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Marinol caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[17]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Marinol caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[18]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Marinol and Olopatadine.	Conjunctiva disorder [9A60]	[19]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Marinol and Ethanol.	Cystitis [GC00]	[19]
Aprepitant	DM053KT	Moderate	Increased metabolism of Marinol caused by Aprepitant mediated induction of CYP450 enzyme.	Depression [6A70-6A7Z]	[20]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Marinol and Esketamine.	Depression [6A70-6A7Z]	[21]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Marinol caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[22]
Brimonidine	DMQLT4N	Moderate	Additive CNS depression effects by the combination of Marinol and Brimonidine.	Glaucoma [9C61]	[23]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Marinol caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[24]
Delavirdine	DM3NF5G	Minor	Decreased metabolism of Marinol caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[25]
Efavirenz	DMC0GSJ	Moderate	Increased metabolism of Marinol caused by Efavirenz mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[26]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Marinol caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[27]
Ritonavir	DMU764S	Minor	Increased metabolism of Marinol caused by Ritonavir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[28]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Marinol and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[29]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Marinol caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[30]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Marinol caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[21]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Marinol and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[31]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Marinol and Lasmiditan.	Migraine [8A80]	[32]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Marinol caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[33]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Marinol and Thalidomide.	Multiple myeloma [2A83]	[34]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Marinol caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[35]
Modafinil	DMYILBE	Minor	Increased metabolism of Marinol caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[36]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Marinol and Bupropion.	Nicotine use disorder [6C4A]	[37]
Levomethadyl Acetate	DM06HG5	Major	Additive CNS depression effects by the combination of Marinol and Levomethadyl Acetate.	Opioid use disorder [6C43]	[38]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Marinol and Apraclonidine.	Optic nerve disorder [9C40]	[23]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Marinol caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[39]
Dextropropoxyphene	DM23HCX	Major	Decreased metabolism of Marinol caused by Dextropropoxyphene mediated inhibition of CYP450 enzyme.	Pain [MG30-MG3Z]	[40]
Buprenorphine	DMPRI8G	Major	Additive CNS depression effects by the combination of Marinol and Buprenorphine.	Pain [MG30-MG3Z]	[41]
Biperiden	DME78OA	Moderate	Additive CNS depression effects by the combination of Marinol and Biperiden.	Parkinsonism [8A00]	[42]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Marinol caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[43]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Marinol caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[44]
Bosentan	DMIOGBU	Moderate	Increased metabolism of Marinol caused by Bosentan mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[45]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Marinol and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[46]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Marinol caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[21]
Armodafinil	DMGB035	Minor	Increased metabolism of Marinol caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[36]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Marinol caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[47]
Tizanidine	DMR2IQ4	Moderate	Additive CNS depression effects by the combination of Marinol and Tizanidine.	Tonus and reflex abnormality [MB47]	[48]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Marinol and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[46]
Tacrolimus	DMZ7XNQ	Moderate	Increased plasma concentrations of Marinol and Tacrolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[46]
-----------


⏷ Show the Full List of 39 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
FD&C blue no. 1	E00263	19700	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Quinoline yellow WS	E00309	24671	Colorant
Sunset yellow FCF	E00255	17730	Colorant
Ammonia	E00007	222	Alkalizing agent
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Glycerin	E00026	753	Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Water	E00035	962	Solvent
--------------------


⏷ Show the Full List of 15 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Dronabinol 2.5 mg capsule	2.5 mg	Oral Capsule	Oral
Dronabinol 5 mg capsule	5 mg	Oral Capsule	Oral
Dronabinol 10 mg capsule	10 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 018651.
2	Clinical pipeline report, company report or official report of INSYS Therapeutics.
3	BDDCS applied to over 900 drugs
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	Ciccolini J, Serdjebi C, Peters GJ, Giovannetti E: Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective. Cancer Chemother Pharmacol. 2016 Jul;78(1):1-12. doi: 10.1007/s00280-016-3003-0. Epub 2016 Mar 23.
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol. 2009 Feb;156(3):397-411.
8	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
9	CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. Biochem Pharmacol. 2005 Oct 1;70(7):1096-103.
10	Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cells. Br J Cancer. 2005 Feb 28;92(4):696-704.
11	Inhibition of cyclosporine and tetrahydrocannabinol metabolism by cannabidiol in mouse and human microsomes. Xenobiotica. 1996 Mar;26(3):275-84.
12	Health control over the feeding of troops on the Western and 3d Belorussian Fronts during the Great Patriotic War years. Voen Med Zh. 1975 Jun;(6):86-8.
13	THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
14	Gene expression changes in human small airway epithelial cells exposed to Delta9-tetrahydrocannabinol. Toxicol Lett. 2005 Aug 14;158(2):95-107.
15	Inhibiting Heat Shock Proteins Can Potentiate the Cytotoxic Effect of Cannabidiol in Human Glioma Cells. Anticancer Res. 2015 Nov;35(11):5827-37.
16	JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. Oncogene. 2008 Aug 28;27(37):5033-44.
17	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
18	Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
19	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
20	Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
21	Cerner Multum, Inc. "Australian Product Information.".
22	Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
23	Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
24	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
25	Barry M, Mulcahy F, Merry C, Gibbons S, Back D "Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection." Clin Pharmacokinet 36 (1999): 289-304. [PMID: 10320951]
26	Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
27	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
28	Product Information. Norvir (ritonavir). Abbott Pharmaceutical, Abbott Park, IL.
29	Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
30	Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
31	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
32	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
33	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
34	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
35	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
36	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
37	Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
38	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
39	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
40	Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
41	Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
42	Product Information. Artane (trihexyphenidyl). Lederle Laboratories, Wayne, NJ.
43	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
44	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
45	Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
46	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
47	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
48	Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.